1. Patients contraindicated or with history/evidence of hypersensitivity to Molnupiravir administration or any of the components of formulation. <br/ >2. Patients with severe disease <br/ >3. Severe liver disease: underlying liver cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN <br/ >4. Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days <br/ >5. Patients with a history of acute pancreatitis within 3 months <br/ >6. Severe renal impairment [creatinine clearance (CrCl) <30 mL/min] <br/ >7. Having used Molnupiravir or participated in any other interventional clinical study within 30 days

1. Patients contraindicated or with history/evidence of hypersensitivity to Molnupiravir administration or any of the components of formulation. <br/ >2. Patients with severe disease <br/ >3. Severe liver disease: underlying liver cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN <br/ >4. Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days <br/ >5. Patients with a history of acute pancreatitis within 3 months <br/ >6. Severe renal impairment [creatinine clearance (CrCl) <30 mL/min] <br/ >7. Having used Molnupiravir or participated in any other interventional clinical study within 30 days

N/A

N/A

1. Patients contraindicated or with history/evidence of hypersensitivity to Molnupiravir administration or any of the components of formulation. <br/ >2. Patients with severe disease <br/ >3. Severe liver disease: underlying liver cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN <br/ >4. Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days <br/ >5. Patients with a history of acute pancreatitis within 3 months <br/ >6. Severe renal impairment [creatinine clearance (CrCl) <30 mL/min] <br/ >7. Having used Molnupiravir or participated in any other interventional clinical study within 30 days

1. Patients contraindicated or with history/evidence of hypersensitivity to Molnupiravir administration or any of the components of formulation. <br/ >2. Patients with severe disease <br/ >3. Severe liver disease: underlying liver cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN <br/ >4. Patients currently taking nucleos(t)ide analogues/ immunosuppressive treatments within 30 days <br/ >5. Patients with a history of acute pancreatitis within 3 months <br/ >6. Severe renal impairment [creatinine clearance (CrCl) <30 mL/min] <br/ >7. Having used Molnupiravir or participated in any other interventional clinical study within 30 days